{"prompt": "['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', \"All IMP will be dispensed in accordance with the Investigator's prescription and it is the\", \"Investigator's responsibility to ensure that an accurate record of IMP issued and returned is\", 'maintained.', 'Any quality issue noticed with the receipt or use of an IMP (deficiency in condition, appearance,', 'pertaining documentation, labeling, expiration date, etc) must be promptly notified to the Sponsor', '(see Section 10.4.7). Some deficiencies may be recorded through a complaint procedure.', 'A potential defect in the quality of IMP may be subject to initiation of a recall procedure by the', 'Sponsor. In this case, the Investigator will be responsible for promptly addressing any request', 'made by the Sponsor, in order to recall the IMP and eliminate potential hazards.', 'Under no circumstances will the Investigator supply IMP to a third party, allow the IMP to be', 'used other than as directed by this clinical trial protocol, or dispose of IMP in any other manner.', '8.7.1 Treatment accountability and compliance', 'As alemtuzumab will be administered by daily IV infusions in a day hospital supervised medical', 'setting, by qualified center personnel, responsibility for compliance with mandatory safety', 'assessments resides with the Study Investigator.', '8.7.2 Return and/or destruction of treatments', 'For IMP provided by the Sponsor:', 'Reconciliation of all used, partially-used or unused treatments must be performed at the site by the', 'Investigator and the monitoring team using treatment log forms.', 'Written authorization for destruction will be given by the sponsor once the reconciliation has been', 'completed. This destruction can be performed at the site depending on local regulations and site', 'specific capabilities; alternatively, study drug may be returned to the sponsor or designee for', 'destruction. The Investigator will not destroy the used and unused IMP unless the Sponsor', 'provides written authorization.', '8.8', 'CONCOMITANT MEDICATION', 'A concomitant medication is any treatment received by the patient concomitantly to any IMP(s).', 'Concomitant treatments have been detailed for all phases of the study and are not limited to the', 'treatment received with the IMP (treatment phase). Concomitant use of alternative medications', '(eg, herbal treatments, botanicals, etc) for treatment of MS is discouraged due to concerns of', 'possible interactions with study treatment. Patients should be questioned about their use of such', 'nonprescription therapies, all of which will be listed as concomitant medications.', 'Property of the Sanofi Group - strictly confidential', 'Page 50', 'VV-CLIN-0254406: 5.0']['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', 'Prior DMT period', 'Therapy with disease-modifying MS treatments that the patient is currently being administered', '(ie, limited to interferons and GA only) will be permitted during the screening and prior DMT', 'Treatment Phase. If the investigator determines that the patient needs to be treated with another', 'DMT, the patient will be discontinued from the study.', 'Prior DMT will be discontinued 7 days before alemtuzumab first administration. Refer to', 'Section 6.1 for further details.', 'No concomitant therapy with any other disease-modifying MS treatments either licensed or', 'investigational will be permitted during the screening and prior DMT period.', 'Concomitant use of systemic corticosteroids for the treatment of MS relapse is allowed during the', 'DMT period.', 'Alemtuzumab treatment phase', 'Patients who receive any alemtuzumab treatment will continue study participation even if they do', 'not complete the planned treatment regimen. Patients who discontinue study treatment can', 'continue study participation. If a patient is not willing to continue study participation, all efforts', 'should be made to have the EOTP visit performed by the patient.', 'No concomitant therapy with any disease-modifying MS treatments either licensed or', 'investigational, including interferons and GA, will be permitted during the alemtuzumab', 'treatment phase. If the investigator determines that the patient needs to be treated with another', 'DMT, the patient will be discontinued from the study.', 'In addition, no other investigational MS therapy, including investigational symptomatic therapy,', 'will be permitted. Use of live vaccines is specifically prohibited for alemtuzumab-treated patients', 'for the 30 days prior to the first alemtuzumab administration at Month 0 and for the 2 years', 'duration of the alemtuzumab treatment phase of the study.', 'Concomitant use of systemic corticosteroids for the treatment of MS relapse is allowed during this', 'period.', 'Safety monitoring phase', 'The safety of MS disease-modifying drugs in patients who receive alemtuzumab has not been', \"established. Alemtuzumab treatment may have long-lasting, unknown effects on a patient's\", 'immune system. Concomitant therapy with any disease-modifying MS treatments following', 'treatment with alemtuzumab has not been studied in a controlled study conducted by Sanofi', 'Genzyme. Investigators should consider the potential for adverse effects associated with', 'subsequent or concomitant treatment with cytotoxic or immunosuppressant drugs in patients who', 'have received alemtuzumab.', 'Participating patients are prohibited from use of any investigational MS therapy.', 'Property of the Sanofi Group - strictly confidential', 'Page 51', 'VV-CLIN-02544065 5.0']\n\n###\n\n", "completion": "END"}